StockpollyBeta
Get App
Delisting riskPopularity #4,593
GOVX · NASDAQ · Biotechnology

GeoVax Labs (GOVX)

Clinical developer of an mpox/smallpox vaccine and gene-directed therapy for head-and-neck cancer.

$0.3699
vs last close+0.01 (+1.82%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000031210000
Cost of revenue000470555040
Gross profit000−4−51−4−4−50−40
986119221414
Research & development764478555343
211112221111
Selling & marketing000000000000
General & administrative201110221111
Other expenses000−4−70−5−5−50−40
Operating income−9−8−6−5−6−8−5−5−6−4−5−4
000000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income000000000000
Income before tax−8−8−6−5−6−8−5−5−6−4−5−4
Net income from continuing operations−8−8−6−5−6−8−5−5−6−4−5−4
Net income−8−8−6−5−6−8−5−5−6−4−5−4
EPS, basic−$82.75−$74.75−$57.50−$49.75−$22.75−$19.50−$11.25−$8.75−$7.75−$2.55−$2.62−$0.97
EPS, diluted−$82.75−$74.75−$57.50−$49.75−$22.75−$19.50−$11.25−$8.75−$7.75−$2.55−$2.62−$0.97
Weighted average shares, basic000000011125
Weighted average shares, diluted000000011125
EBITDA−9−8−6−5−6−8−5−5−6−5−5−4
Depreciation & amortization000000000000
EBIT−9−8−6−5−6−8−5−5−6−5−5−4